Menu

New Species of Ebola Discovered

The Bombali Ebola virus was identified in bats in Sierra Leone, and there’s no evidence that it has infected people or causes human disease.

Jul 31, 2018
Catherine Offord

ABOVE: Colored transmission electron micrograph of an ebolavirus virion, a member of the same family as the newly discovered virus
WIKIMEDIA, CDC/CYNTHIA GOLDSMITH

Researchers have discovered a new species of Ebola in bats in Sierra Leone, the country’s government announced last week (July 26). Named “Bombali” after the region in which it was found, the virus has not yet been identified in humans, but could still pose a health risk. 

“At this time, it is not yet known if the Bombali Ebola virus has been transmitted to people or if it causes disease in people,” Amara Jambai, a senior ministry of health official, tells AFP. “But it has the potential to infect human cells.” 

An Angolan free-tailed bat, one of the species carrying the new virus
inaturalist, jakob fahr

The research, which was carried out by scientists at Columbia University, the University of California, Davis (UCD), and nonprofit EcoHealth Alliance, has not yet been published. The government of Sierra Leone decided to announce the team’s findings now because “they want to preempt negative rumors, and are rolling out education programs to reduce potential for spillover,” EcoHealth Alliance CEO Peter Daszack tells STAT News

See “Predicting Future Zoonotic Disease Outbreaks

Researchers identified the new virus via fragments of RNA in two species of bats that are widely found across Sub-Saharan Africa. From the RNA fragments, the team was able to reconstruct most of the viral genome, which revealed enough differences from the five existing Ebola viruses to indicate a new species.

The genome also revealed that the virus possesses a protein on its exterior that likely allows it to infect human cells. But “just because it enters human cells doesn’t mean it will cause human disease,” Stuart Nichol, chief of the viral special pathogens branch at the Centers for Disease Control and Prevention (CDC), tells STAT.

CDC researchers are now working to extract a whole infectious virus from samples taken from the bats in Sierra Leone. In the meantime, researchers are advising people living in the Bombali region to avoid bats. 

“We don’t really know where on the spectrum [the Bombali virus] stands,” UCD pathologist Tracey Goldstein tells Science News. For now, “I don’t think people should be alarmed.” 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.